In order to demonstrate that the dysregulation in the nucleus by the CMT-mutant is linked to the disease mechanism and knowing that this dysregulation involves multiple genes and associated TFs, we applied a general strategy for alleviating the TyrRS neurotoxicity via inhibiting its nuclear import both genetically and pharmacologically. This evidence concerns the gene YARS1 and Charcot-Marie-Tooth disease.